Short Interest in Cryoport, Inc. (NASDAQ:CYRX) Decreases By 7.4%

Cryoport, Inc. (NASDAQ:CYRX) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 2,500,000 shares, a decrease of 7.4% from the November 15th total of 2,700,000 shares. Currently, 5.3% of the company’s stock are sold short. Based on an average daily volume of 442,400 shares, the days-to-cover ratio is presently 5.7 days.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. UBS Group upped their target price on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a research report on Friday, October 18th. Roth Mkm lowered their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $12.50.

Insider Buying and Selling

In other news, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $6.78, for a total transaction of $339,000.00. Following the sale, the chief executive officer now owns 712,747 shares of the company’s stock, valued at approximately $4,832,424.66. This trade represents a 6.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the transaction, the director now owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 109,869 shares of company stock worth $735,673. 10.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Comerica Bank raised its stake in Cryoport by 73.0% during the first quarter. Comerica Bank now owns 3,481 shares of the company’s stock worth $62,000 after acquiring an additional 1,469 shares in the last quarter. Quest Partners LLC increased its holdings in Cryoport by 1,083,000.0% in the second quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock worth $75,000 after purchasing an additional 10,830 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Cryoport during the third quarter worth $82,000. Hsbc Holdings PLC bought a new stake in Cryoport in the 2nd quarter valued at about $92,000. Finally, Intech Investment Management LLC bought a new position in shares of Cryoport in the 3rd quarter worth $105,000. 92.90% of the stock is currently owned by institutional investors.

Cryoport Stock Up 0.4 %

NASDAQ CYRX traded up $0.03 during trading hours on Monday, hitting $7.72. 266,647 shares of the company traded hands, compared to its average volume of 560,202. The stock has a market capitalization of $381.61 million, a price-to-earnings ratio of -2.32 and a beta of 1.62. Cryoport has a twelve month low of $5.32 and a twelve month high of $20.10. The business’s 50-day moving average is $7.31 and its 200-day moving average is $8.08. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.